Posted by Michael Wonder on 29 Sep 2020
Epidyolex oral solution is not included in the high-cost protection
29 September 2020 - On 28 September 2020, it was decided that Epidyolex is not included in the high-cost protection.
The benefits of treatment with Epidyolex primarily affect quality of life and not survival. In the absence of clinical studies evaluating quality of life, TLV assesses that the quality of life benefits for patients with DS and LGS are associated with very high uncertainties.
TLV also believes that there are major uncertainties regarding the cost of personal assistance. There is no evidence to show a reduced need for assistance with fewer epileptic seizures.
